SANTIAGO, CHILE--(Business Wire / Korea Newswire)--Masimo (NASDAQ: MASI) today announced that its Founder and CEO, Joe Kiani, will be a featured speaker tomorrow, April 17, at the 6th Global Ministerial Summit on Patient Safety. Kiani’s speech, “Empowering Patient Safety Through AI,” will discuss how artificial intelligence-based technologies, by analyzing both historical and immediate data, can help clinicians prevent errors of omission, improving patient safety, patient outcomes, and clinician efficiency.

As Kiani will note, Masimo’s AI-powered medical technologies, including those used as part of the Masimo Hospital Automation™ family of solutions available today, can ease the burden of staffing shortages by improving clinician efficiency. Furthermore, by integrating and analyzing patient data from a variety of sources, in real time, such technology can provide greater situational awareness than alarms alone and help predict increases in patient risk, prompting clinicians to intervene sooner to catch physiological deterioration before a patient’s condition worsens.

“We introduced the Halo engine in 2010,” said Kiani. “Halo is the first predictive algorithm to incorporate learnings from expert clinicians to identify deterioration patterns in multiple physiological parameters simultaneously in real time to help clinicians identify patient safety issues before it’s too late. Without AI, these types of solutions would not be possible. We’re proud to be at the forefront of this very promising avenue of improving patient safety and patient care. AI - when implemented with the ingenuity, integrity, and expertise Masimo is known for - has the predictive power to help clinicians shape robust streams of patient data - both historical and immediate - into meaningful, actionable insights about their patients. Tools such as Halo ION® and the newly introduced Opioid Halo™, soon to be joined by Sepsis Halo, Activity Halo, and more, can help clinicians prioritize patient needs, make more informed decisions and more efficient diagnoses, and streamline workflows in numerous ways. At Masimo, we have always championed patient safety, and we’re particularly excited to collaborate with caregivers around the world to advance patient safety using AI.”

For more information about the Global Ministerial Summit, please visit psschile.minsal.cl. For more information about Masimo and its innovative solutions, please visit www.masimo.com.

Halo, Sepsis Halo, Activity Halo, and AI-based algorithms for Halo ION are not FDA cleared.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2 improve CCHD screening in newborns3 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.4-7 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,8 and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2022-23 U.S. News and World Report Best Hospitals Honor Roll.9 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7®, Radius PPG®, and Radius VSM™, portable devices like Rad-67®, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97® and the Masimo W1® medical watch. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo ION®, UniView®, UniView :60™, and Masimo SafetyNet®. Its growing portfolio of health and wellness solutions includes Radius Tº®, Masimo W1 Sport, and Masimo Stork™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

RPVi has not received FDA 510(k) clearance and is not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

1. Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
2. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
3. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
4. Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
5. Taenzer A et al. Postoperative Monitoring - The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
6. McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
7. McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
8. Estimate: Masimo data on file.
9. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo Hospital Automation™, Halo, Halo ION®, Opioid Halo™, Sepsis Halo, and Activity Halo. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo‘s unique noninvasive measurement technologies, including Hospital Automation, Halo, Halo ION, Opioid Halo, Sepsis Halo, and Activity Halo, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to the assumption that Sepsis Halo, Activity Halo, and more tools will soon be developed; risks related to COVID-19; as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (“SEC”), which may be obtained for free at the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240416246961/en/

Website: http://www.masimo.com View Korean version of this release Contact Masimo
Evan Lamb
949-396-3376
[email protected]
This news is a press release provided by Masimo Corporation. Korea Newswire follows these editorial guidelines. Masimo Corporation News ReleasesSubscribeRSS 마시모 설립자 겸 최고경영자 조 키아니, 칠레 글로벌 환자 안전 정상회의에서 AI 주제로 연설 마시모(Masimo) (나스닥: MASI)의 설립자 겸 최고경영자 조 키아니(Joe Kiani)가 내일 4월 17일 개최되는 제6회 환자 안전에 관한 장관급 정상회의(Global Ministerial Summit on Patient Safety)에 특별 연사로 연설한다. ‘인공지능을 통한 환자 안전 강화(Empowering Patient Safety Through AI)’라는 주제... 4월 18일 14:15 New Study Finds Significant Correlation Between Masimo ORi™ and Arterial Partial Pressure of Oxygen During One-Lung Ventilation Masimo (NASDAQ: MASI) today announced the findings of a retrospective study published in the Journal of Anesthesia in which Dr. Yu Jeong Bang and colleagues at the Samsung Medical Center, Sungkyunkwan University School of Medicine, in Seoul, South Korea, investigated the association of ... 2023년 12월 12일 16:30 ... More  More News Health Medical Appliances People Overseas Masimo Corporation All News Releases 